Article

Open Access  |  Editorial
Cancer Drug Resist 2018;1:198-9. 10.20517/cdr.2018.29 © The Author(s) 2018.

Acknowledgement to reviewers of Cancer Drug Resistance in 2018

Views: 1121 |  Downloads: 771 |  Cited:  0

OAE Publishing Inc., Chaoyang District, Beijing 100027, China.

Correspondence Address: OAE Publishing Inc., Suite 601, Tower A, TYG Center, C2 North Road, East 3rd Ring Road, Chaoyang District, Beijing 100027, China. E-mail: editorial@cdrjournal.com

© The Author(s) 2018. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The editors of the Cancer Drug Resistance would like to take this opportunity to express their sincere gratitude to the reviewers and guest editors for assessing manuscripts in 2018 [Table 1].

Table 1

Names of reviewers and guest editors

Names
Amstutz, Ursula Jansen, Gerrit
Ahmad, Aamir Jiang, Zhao
Balboni, Beatrice Joerger, Markus
Ciriza, Jesús Kwok, Hang Fai
Cloos, Jacqueline Link, Wolfgang
Del Re, Marzia Marchesi, Federica
El Hassouni, Btissame Matsuura, Yoshiyuki
Fenton, Tim Michaelis, Martin
Fiandalo, Michael Mini, Enrico
Firuzi, Omid Nobili, Stefania
Gan, Boyi Nowak-Sliwinska, Patrycja
Garajová, Ingrid Pasternak, Amy
Garrett, Michelle Perego, Paola
Giovannetti, Elisa Phillips, Roger M
Gong, Li Pore, Milind
Griffiths, Elizabeth Rodriguez, Jose Antonio
Huang, Shiliang Rosière, Rémi
Huisman, M.C. Wass, Mark
Hussain, Suleman Zaffaroni, Nadia

Declarations

Authors’ contributions

Writing and revision of the article and approved the final version: Cancer Drug Resistance Editorial Office

Availability of data and materials

Not applicable.

Financial support and sponsorship

None.

Conflicts of interest

All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2018.

Cite This Article

OAE Style

Cancer Drug Resistance Editorial Office. Acknowledgement to reviewers of Cancer Drug Resistance in 2018. Cancer Drug Resist 2018;1:198-9. http://dx.doi.org/10.20517/cdr.2018.29

AMA Style

Cancer Drug Resistance Editorial Office. Acknowledgement to reviewers of Cancer Drug Resistance in 2018. Cancer Drug Resistance. 2018; 1(4): 198-9. http://dx.doi.org/10.20517/cdr.2018.29

Chicago/Turabian Style

Cancer Drug Resistance Editorial Office, . 2018. "Acknowledgement to reviewers of Cancer Drug Resistance in 2018" Cancer Drug Resistance. 1, no.4: 198-9. http://dx.doi.org/10.20517/cdr.2018.29

ACS Style

Cancer Drug, Resistance Editorial Office. Acknowledgement to reviewers of Cancer Drug Resistance in 2018. Cancer Drug Resist. 2018, 1, 198-9. http://dx.doi.org/10.20517/cdr.2018.29

Views
1121
Downloads
771
Citations
0
Comments
0
16

Related

Open Access Review
Targeting BCL2 pathways in CLL: a story of resistance and ingenuity
Available online: 26 Nov 2023
Open Access Review
Supramolecular host-guest nanosystems for overcoming cancer drug resistance
Available online: 21 Nov 2023
Open Access Review
Emerging roles of 3D-culture systems in tackling tumor drug resistance
Available online: 20 Nov 2023
Open Access Review
Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies
Available online: 16 Nov 2023
Open Access Review
Unlocking antitumor immunity with adenosine receptor blockers
Available online: 24 Oct 2023
Open Access Review
Recent advances in natural compounds inducing non-apoptotic cell death for anticancer drug resistance
Available online: 18 Oct 2023
Open Access Original Article
Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity
Available online: 16 Oct 2023
Open Access Review
Drug resistance in glioblastoma: from chemo- to immunotherapy
Available online: 10 Oct 2023
Open Access Review
Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia
Available online: 25 Sep 2023
Open Access Review
A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer
Available online: 24 Sep 2023

Comments

Comments must be written in English. Spam, offensive content, impersonation, and private information will not be permitted. If any comment is reported and identified as inappropriate content by OAE staff, the comment will be removed without notice. If you have any queries or need any help, please contact us at support@oaepublish.com.

0
Cite This Article 0 clicks
Commentary 0 comments
Like This Article 16 likes
Share This Article
Scan the QR code for reading!
See Updates
Contents
Figures
Related
Hot Topics
Resistance | Drug delivery | Nanomedicine | Tumor microenvironment | Immune checkpoint inhibitors | Target therapy | Immunotherapy | Radiotherapy | Ferroptosis | PARP inhibitors | MYC | ABC transporters | Autophagy | Metabolism | Mechanisms | Precision medicine | Extracellular vesicles | Stem cell | Biomarker | Ovarian cancer | Renal cell carcinoma | Prostate cancer | Breast cancer | Colorectal cancer | Myeloid leukemia | Non-small cell lung cancer | Pancreatic cancer | Head and neck cancer | Squamous cell carcinoma | Mitochondria |
Cancer Drug Resistance
ISSN 2578-532X (Online)
Follow Us

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/